Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 2
2010 3
2011 4
2012 1
2013 2
2017 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

12 results

Results by year

Filters applied: . Clear all
Page 1
Showing results for trospium xr
Your search for rospium-xr retrieved no results
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials.
Staskin DR, Rosenberg MT, Sand PK, Zinner NR, Dmochowski RR. Staskin DR, et al. Int J Clin Pract. 2009 Dec;63(12):1715-23. doi: 10.1111/j.1742-1241.2009.02189.x. Int J Clin Pract. 2009. PMID: 19930332 Clinical Trial.
PURPOSE: We analysed pooled data from two identically designed phase III trials of a once-daily, extended-release (XR) formulation of trospium chloride (trospium XR 60-mg capsules) in subjects with overactive bladder syndrome (OAB). ...The most frequen …
PURPOSE: We analysed pooled data from two identically designed phase III trials of a once-daily, extended-release (XR) formulation of …
Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder.
MacDiarmid SA, Ellsworth PI, Ginsberg DA, Oefelein MG, Sussman DO. MacDiarmid SA, et al. Urology. 2011 Jan;77(1):24-9. doi: 10.1016/j.urology.2010.07.469. Epub 2010 Oct 23. Urology. 2011. PMID: 20970833 Clinical Trial.
Patients received either trospium XR 60 mg or placebo once daily for 12 weeks. RESULTS: The mean age was 66.2 years for trospium XR and 63.1 years for placebo. ...Two trospium XR patients (2.1%) developed urinary retention; both were aged …
Patients received either trospium XR 60 mg or placebo once daily for 12 weeks. RESULTS: The mean age was 66.2 years for tro …
Once-daily administration of trospium chloride extended release provides 24-hr coverage of nocturnal and diurnal symptoms of overactive bladder: an integrated analysis of two phase III trials.
Ginsberg DA, Oefelein MG, Ellsworth PI. Ginsberg DA, et al. Neurourol Urodyn. 2011 Apr;30(4):563-7. doi: 10.1002/nau.21018. Epub 2011 Jan 25. Neurourol Urodyn. 2011. PMID: 21268101 Clinical Trial.
This analysis examined the effects of trospium XR on diurnal and nocturnal OAB symptoms. METHODS: Pooled data were analyzed from two identically designed Phase III trials in which patients with OAB were randomized to receive trospium XR 60 mg or placeb …
This analysis examined the effects of trospium XR on diurnal and nocturnal OAB symptoms. METHODS: Pooled data were analyzed fr …
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials.
Sand PK, Rovner ES, Watanabe JH, Oefelein MG. Sand PK, et al. Drugs Aging. 2011 Feb 1;28(2):151-60. doi: 10.2165/11586740-000000000-00000. Drugs Aging. 2011. PMID: 21275440 Clinical Trial.
RESULTS: Concomitant medications were being taken by 1135 subjects (placebo, n = 576; trospium chloride XR, n = 559); 427 were taking seven or more (placebo, n = 199; trospium XR, n = 228). ...Logistic regression analysis indicated that the odds of exp …
RESULTS: Concomitant medications were being taken by 1135 subjects (placebo, n = 576; trospium chloride XR, n = 559); 427 were …
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms.
Zinner NR, Dmochowski RR, Staskin DR, Siami PF, Sand PK, Oefelein MG. Zinner NR, et al. Neurourol Urodyn. 2011 Sep;30(7):1214-9. doi: 10.1002/nau.21000. Epub 2011 Apr 1. Neurourol Urodyn. 2011. PMID: 21462240
This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium XR. METHODS: Following double-blind treatment, subjects with OAB could enter the open-label period, during which they received …
This pooled analysis of the 9-month open-label extensions to these studies evaluated the long-term efficacy and tolerability of trospium …
Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects.
Harnett MD, Shipley J, MacLean L, Schwiderski U, Sandage BW Jr. Harnett MD, et al. Clin Drug Investig. 2013 Feb;33(2):133-41. doi: 10.1007/s40261-012-0039-8. Clin Drug Investig. 2013. PMID: 23203138
STUDY DESIGN: Pharmacokinetic data were obtained from three studies in which a total of 349 subjects received trospium chloride XR for up to 12 weeks. Plasma trospium chloride concentration data were pooled and a population pharmacokinetic model was derived u …
STUDY DESIGN: Pharmacokinetic data were obtained from three studies in which a total of 349 subjects received trospium chloride XR …
Gateways to clinical trials.
Tomillero A, Moral MA. Tomillero A, et al. Methods Find Exp Clin Pharmacol. 2010 Jul-Aug;32(6):437-61. doi: 10.1358/mf.2010.32.6.1538165. Methods Find Exp Clin Pharmacol. 2010. PMID: 20852754 Free article.
A-3309, Abobotulinumtoxin A, Adalimumab, AIDSVAX gp120 B/E, ALVAC E120TMG, Atorvastatin calcium; Bepridil, Bevacizumab; Candesartan cilexetil, Capecitabine, Cetuximab, Clopidogrel; Dapagliflozin, Dasatinib, Denosumab, Dexmedetomidine hydrochloride, Diacetylmorphine, Diannexin, Do …
A-3309, Abobotulinumtoxin A, Adalimumab, AIDSVAX gp120 B/E, ALVAC E120TMG, Atorvastatin calcium; Bepridil, Bevacizumab; Candesartan cilexeti …
Effect of Trospium Chloride on Cognitive Function in Women Aged 50 and Older: A Randomized Trial.
Geller EJ, Dumond JB, Bowling JM, Khandelwal CM, Wu JM, Busby-Whitehead J, Kaufer DI. Geller EJ, et al. Female Pelvic Med Reconstr Surg. 2017 Mar/Apr;23(2):118-123. doi: 10.1097/SPV.0000000000000374. Female Pelvic Med Reconstr Surg. 2017. PMID: 28067745 Clinical Trial.
Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. Baseline cognitive function was assessed via Hopkins Verbal Learning Test-Revised (HVLT-R), Mini Mental Status Exam, Mini Mental Status X, D …
Women aged 50 years or older seeking treatment for OAB were randomized to either trospium chloride XR 60 mg daily or placebo. …
Effect of concomitant administration of trospium chloride extended release on the steady-state pharmacokinetics of metformin in healthy adults.
Oefelein MG, Tong W, Kerr S, Bhasi K, Patel RK, Yu D. Oefelein MG, et al. Clin Drug Investig. 2013 Feb;33(2):123-31. doi: 10.1007/s40261-012-0049-6. Clin Drug Investig. 2013. PMID: 23325481 Free PMC article. Clinical Trial.
METHODS: In a single-centre, randomized, open-label, two-group, two-period study in healthy males and females aged 18-45 years, 44 subjects received oral metformin 500 mg twice daily for 3.5 days during one period, and oral trospium chloride XR 60 mg once daily for …
METHODS: In a single-centre, randomized, open-label, two-group, two-period study in healthy males and females aged 18-45 years, 44 subjects …
Baseline incontinence severity is predictive of the percentage of patients continent after receiving once-daily trospium chloride extended release.
Staskin DR, Cardozo L. Staskin DR, et al. Int J Clin Pract. 2009 Jun;63(6):973-6. doi: 10.1111/j.1742-1241.2009.02065.x. Epub 2009 May 4. Int J Clin Pract. 2009. PMID: 19459997 Clinical Trial.
The objective of this study was to stratify and analyse the effects of baseline incontinence disease severity on the treatment outcome of the percentage of patients continent (PPC) during treatment with once-daily trospium chloride 60 mg extended release (XR). METHO …
The objective of this study was to stratify and analyse the effects of baseline incontinence disease severity on the treatment outcome of th …
12 results